BACKGROUND: While prior studies have supported clinical and health-related quality-of-life benefits of dalfampridine extended release tablets (D-ER; fampridine outside the US, 10 mg twice daily) in persons with multiple sclerosis (MS), there are limited real-world data on economic benefits as measured by healthcare resource utilization. OBJECTIVES: To evaluate healthcare resource utilization associated with D-ER. METHODS: Using the HealthCore Integrated Research Database^SMof administrative claims from a large, geographically diverse, US population between 1/1/2009 and 2/28/2013, resource utilization was compared between patients with MS treated with D-ER versus not. Patients aged ≥18 years; with ≥2 pre-index MS-related medical or pharmacy claims and ≥12 months each of pre-index and post-index continuous enrollment; and without prior claims for D-ER and alternate gait-impairing etiologies were included. The D-ER cohort had ≥1 D-ER claim from 1/1/2010 to 2/29/2012, while the cohort not receiving D-ER had ≥1 medical claim(s) with a walking-attributable code (ICD-9-CM 781.2, 719.7, 781.0, 781.3) and no D-ER use; in both cohorts the index date was the earliest relevant claim. The cohorts were propensity-score matched on baseline demographics, comorbidities, and MS-related resource utilization. Walking-attributable hospitalizations, emergency department (ED), neurologist office, and physical or occupational therapy visits were compared from baseline to 1-year follow-up between cohorts. RESULTS: